Inventor · disambiguated record
Ulrik Nielsen
Also filed as: NIELSEN ULRIK · NIELSEN ULRIK B · NIELSEN ULRIK BJERL
24 granted patents·31 pending applications·319 citations·filing 2001–2024
97Inventor score
Files withMERRIMACK PHARMACEUTICALS INC24SILVER CREEK PHARMACEUTICALS INC7SCHOEBERL BIRGIT4UNIV CALIFORNIA3BUKHALID RAGHIDA2
Top patents by PatentIndex Score
55 records- 0198US7846440B2Antibodies against ErbB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·92 cites·18 claims
- 0295US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0394US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0494US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0594US8961966B2Antibodies against ERBB3 and uses thereofSCHOEBERL BIRGIT·Filed 2010·Granted Feb 24, 2015·20 cites·15 claims
- 0694US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0794US8691225B2Antibodies against the ectodomain of ErbB3 and uses thereofSCHOEBERL BIRGIT·Filed 2009·Granted Apr 8, 2014·26 cites·20 claims
- 0894US8124085B2Bispecific binding agents for modulating biological activityNIELSEN ULRIK B·Filed 2005·Granted Feb 28, 2012·29 cites·9 claims
- 0993US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 1093US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 1191US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 1291US8440192B2Bispecific binding agents for modulating biological activityNIELSEN ULRIK B·Filed 2012·Granted May 14, 2013·11 cites·21 claims
- 1390US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 1490US2024360243A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 1589US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 1689US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1788US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 1887US11471490B2T cells surface-loaded with immunostimulatory fusion molecules and uses thereofTORQUE THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·9 cites·30 claims
- 1987US8623592B2Methods and systems for predicting response of cells to a therapeutic agentSCHOEBERL BIRGIT·Filed 2009·Granted Jan 7, 2014·9 cites·11 claims
- 2087US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2185US9487588B2Antibodies against the ectodomain of ERBB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·4 cites·4 claims
- 2284US9044460B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofBUKHALID RAGHIDA·Filed 2011·Granted Jun 2, 2015·9 cites·12 claims
- 2382US8691231B2Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodiesBUKHALID RAGHIDA·Filed 2012·Granted Apr 8, 2014·7 cites·17 claims
- 2479US2022204642A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2569US2010056761A1Antibodies against erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2669US2019292271A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2767US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2865US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2963US2017073427A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3063US2024002331A1Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereofTIDAL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3161US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 3261US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 3361US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 3461US2014170668A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3559US2017356049A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3658US2017307631A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3757US2011027291A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 3856US2025302958A1Improved cell therapiesUNIKUM THERAPEUTICS APS·Filed 2023·Application pending·0 cites
- 3956US2006115808A1Microarrays of functional biomolecules, and uses thereforUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 4056US2022218614A1Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereofTIDAL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4155US2013183311A1Bispecific binding agents for modulating biological activityMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4255US2016083800A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4354US2023331804A1Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sitesFRED HUTCHINSON CANCER CENTER·Filed 2020·Application pending·0 cites
- 4454US2017210809A1Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4552US2006115810A1Microarrays of functional biomolecules, and uses thereforHARVARD COLLEGE·Filed 2005·Application pending·0 cites
- 4652US2006115809A1Microarrays of functional biomolecules, and uses thereforUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 4750US2012244163A1Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereofSCHOEBERL BIRGIT·Filed 2012·Application pending·0 cites
- 4848US2023302049A1Methods for treating cancer and autoimmune and inflammatory diseasesUNIKUM THERAPEUTICS APS·Filed 2021·Application pending·0 cites
- 4947US2006263801A1Methods of high-throughput screening for internalizing antibodiesUNIV CALIFORNIA·Filed 2006·Application pending·0 cites
- 5047US2015368361A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ulrik Nielsen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →